Team:Paris Bettencourt/Achievements
From 2012.igem.org
Zmarinkovic (Talk | contribs) (→Achievements of all the different modules) |
Zmarinkovic (Talk | contribs) (→Achievements of all the different modules) |
||
Line 71: | Line 71: | ||
+ | <table id="tableboxed"> | ||
+ | <tr> | ||
+ | <td> | ||
+ | '''Achievements''' | ||
+ | |||
+ | *Construction of colicin-like toxin by fusing Colicin E2 based "Synthetic Import Domain" with RNAse domain of colicin D | ||
+ | *Constructon of FseI, I-SceI, LuxR active fragment, LacZ alpha fragment, PyrF and T7 RNA polymerase fused to the two types of "Synthetic Import Domains" from Colicin E2 and Colicin D | ||
+ | *Proof of concept with LacZ alpha fragment fused to "Synthetic Import Domain" from Colicin D | ||
+ | |||
+ | </td> | ||
+ | </tr> | ||
+ | </table> | ||
Revision as of 00:37, 27 September 2012
Achievements of all the different modules
Achievements :
The first part (supD) is well characterized and works well. For the second parts, it turns out that this mutation is quite leaky, although it works in lab conditions, one mutation is not enough if we want to release such parts in nature. Other reasons emphasize this observation, notably the weakness of being at one mutation to recover the protein functionality.
|
Achievements :
|
Achievements : We showed that Colicin E2 cells induce cell death in sensitive populations, and that these sensitive populations can be protected by providing them with our engineered immunity protein.
Part K914001 is well characterized and provides immunity to sensitive cells against the Colicin E2 activity protein, but is leaky. Part K914002 is promoterless and allows users to easily plug in the appropriate promoter for their desired purpose.
|
Achievements
|
Achievements
|